Search
for
Sort by
Research 61–90 of 72
- Hutchinson-Gilford Progeria Syndrome: Premature Aging
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases
- Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science
- Cancer-Related Alopecia Risk and Treatment
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
- Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
- Pustular Eruption in a Patient Treated With Trametinib
- Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Dyad of infantile cutaneous and thymic Langerhans cell histiocytosis: Is it rare?
- 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies
- Hydrogel-Forming Microneedles for Transdermal Drug Delivery
- Biological therapy in the treatment of melanoma
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Drug-induced acne
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia in Association with Malignancy: A Review